Adefovir dipivoxil

Adefovir dipivoxil (trade names Preveon and Hepsera) is an antiviral acyclic nucleoside phosphonate (ANP) analog. It is a dipivoxil formulation of adefovir, a nucleoside reverse transcriptase inhibitor analog of adenosine with activity against hepatitis B virus (HBV), herpes virus, and human immunodeficiency virus (HIV). It is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) that works by blocking reverse transcriptase for the treatment of hepatitis B. Adefovir dipivoxil is not effective against HIV-1.

Properties:
Appearance & Physical State: It has broad-spectrum antiviral activity
Density: 1.35 g/cm3
Boiling Point: 641ºC at 760 mmHg
Melting Point: 98-102ºC
Refractive Index: 1.569
Vapor Pressure: 2.52E-16mmHg at 25°C

Reverse Transcriptase Inhibitors Related Prodcuts:

Didanosine; Dapivirine; Tenofovir; Emtricitabine; Entecavir; Entecavir hydrate; Adefovir; Nevirapine; Lamivudine; Stavudine; Telbivudine; Etravirine; Zidovudine; Zalcitabine; Alovudine

[1]. Marcellin, P., et al., Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med, 2003. 348(9): p. 808-16.

[2]. Manolakopoulos, S., et al., Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Aliment Pharmacol Ther, 2008. 27(3): p. 266-73.